Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Buy recommendation. Analyst Price Forecast Suggests 99.16% Upside As of ...

The two companies have inked an exclusive product licensing agreement that lets Bayer develop and commercialize 10 varieties of salad greens invented by Pairwise using the Durham company’s Fulcrum ...